AstraZeneca has agreed to buy Omthera Pharmaceuticals for up to $443 million to build up its cardiovascular drug business, which Britain's second biggest drugmaker has previously identified as a priority area.
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment